Is Madrigal Pharmaceuticals (MDGL) Undervalued After Wider Losses In Its Second Quarter Results?

Madrigal Pharmaceuticals (MDGL) drew fresh attention on July 30, 2026, after reporting second quarter and six month results that showed wider net losses compared with the same periods a year earlier.

See our latest analysis for Madrigal Pharmaceuticals.

The latest results have coincided with pressure on Madrigal Pharmaceuticals' share price, which closed at $467.32 after falling 5.23% on the day and 14.18% over the past week. However, the 1 year total shareholder return of 54.65% points to strong longer term gains that may still be informing how investors weigh growth potential against rising losses.

If this earnings move has you reassessing opportunities in healthcare, it could be a good moment to scan a wider set of specialised drug developers through a focused screener such as 41 healthcare AI stocks.

After a sharp pullback and a run that still leaves Madrigal Pharmaceuticals up strongly over 1 and 3 years, the valuation question gets sharper. Is most of the upside already behind the stock, or could more still lie ahead?

Most Popular Narrative: 31.1% Undervalued

Compared with Madrigal Pharmaceuticals' last close at $467.32, the most widely followed narrative anchors on a fair value near $678.71 and sets out a detailed MASH growth story that hinges on one core drug and a large potential patient pool.

The rapid uptake and long-term patent protection of Rezdiffra, supported by a new U.S. patent that extends exclusivity to 2045, provides decades of protected revenue opportunity; this increases the likelihood of sustained top-line growth and supports margin expansion due to extended pricing power.

Read the complete narrative.

Want to see how this Rezdiffra thesis translates into long range revenue curves, margin rebuilding, and a richer earnings profile? The core assumptions behind that path are bolder than many investors might expect.

Result: Fair Value of $678.71 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Madrigal Pharmaceuticals upside story still leans heavily on a single drug, while rising competition and reimbursement pressure could limit future pricing power and uptake.

Find out about the key risks to this Madrigal Pharmaceuticals narrative.

Next Steps

With optimism around Madrigal Pharmaceuticals still in focus, this is a good time to review the data yourself and pressure test the story. To see what those positives look like in detail, start with the 3 key rewards.

Looking for more investment ideas beyond Madrigal Pharmaceuticals?

If Madrigal Pharmaceuticals has you thinking harder about where to put fresh capital, do not stop here. There are plenty of other stocks that could fit your goals.

• Target resilient income by scanning companies built around reliable payouts with the help of 9 dividend fortresses.
• Hunt for quality at a reasonable price and see which stocks stand out on valuation and fundamentals through the 55 high quality undervalued stocks.
• Spot potential future standouts early by filtering for strong fundamentals and under-the-radar stories using the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com